Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
30.26
+0.20 (0.67%)
At close: Jul 31, 2025, 4:00 PM
30.26
0.00 (0.00%)
After-hours: Jul 31, 2025, 4:10 PM EDT
Exscientia Revenue
Kiniksa Pharmaceuticals International, had revenue of $156.80M in the quarter ending June 30, 2025, with 44.34% growth. This brings the company's revenue in the last twelve months to $529.33M, up 56.18% year-over-year. In the year 2024, Kiniksa Pharmaceuticals International, had annual revenue of $423.24M with 56.60% growth.
Revenue (ttm)
$529.33M
Revenue Growth
+56.18%
P/S Ratio
4.12
Revenue / Employee
$1,680,419
Employees
315
Market Cap
2.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 423.24M | 152.98M | 56.60% |
Dec 31, 2023 | 270.26M | 50.08M | 22.74% |
Dec 31, 2022 | 220.18M | 181.64M | 471.24% |
Dec 31, 2021 | 38.54M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KNSA News
- 2 days ago - Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewsWire
- 7 days ago - Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewsWire
- 6 weeks ago - Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast - Seeking Alpha
- 2 months ago - Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis - GlobeNewsWire
- 2 months ago - Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Kiniksa Pharmaceuticals: Making Steady Progress - Seeking Alpha
- 3 months ago - Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis - GlobeNewsWire